PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS
Abstract The invention relates to a compound of formula (I) 2 R ,R3 N N---N I R1N%---N \ A¨R4 (I) including pharmaceutically acceptable salts or esters thereof. The compound of formula (I) can be used as a medicament, for example, in the treatment or prophylaxis of pain, atherosclerosis, age-related...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SCHULZ-GASCH, TANJA ROGERS-EVANS, MARK ROEVER, STEPHAN GRETHER, UWE KIMBARA, ATSUSHI NETTEKOVEN, MATTHIAS BENDELS, STEFANIE |
| description | Abstract The invention relates to a compound of formula (I) 2 R ,R3 N N---N I R1N%---N \ A¨R4 (I) including pharmaceutically acceptable salts or esters thereof. The compound of formula (I) can be used as a medicament, for example, in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis. Date recue/Date Received 2020-08-28
L'invention concerne un composé de formule (I) où A et R1 à R4 sont définis tels que dans la description et les revendications. Le composé de formule (I) peut être utilisé en tant que médicament. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2903588C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2903588C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2903588C3</originalsourceid><addsrcrecordid>eNrjZNAOCA3y9HNVcHEN8gxzDPEMcw1WcAxWcHYyUghydXYNCPEPUnB09_fzDA4J5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORpYGxqYWFs7GhFUAAORGJA4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS</title><source>esp@cenet</source><creator>SCHULZ-GASCH, TANJA ; ROGERS-EVANS, MARK ; ROEVER, STEPHAN ; GRETHER, UWE ; KIMBARA, ATSUSHI ; NETTEKOVEN, MATTHIAS ; BENDELS, STEFANIE</creator><creatorcontrib>SCHULZ-GASCH, TANJA ; ROGERS-EVANS, MARK ; ROEVER, STEPHAN ; GRETHER, UWE ; KIMBARA, ATSUSHI ; NETTEKOVEN, MATTHIAS ; BENDELS, STEFANIE</creatorcontrib><description>Abstract The invention relates to a compound of formula (I) 2 R ,R3 N N---N I R1N%---N \ A¨R4 (I) including pharmaceutically acceptable salts or esters thereof. The compound of formula (I) can be used as a medicament, for example, in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis. Date recue/Date Received 2020-08-28
L'invention concerne un composé de formule (I) où A et R1 à R4 sont définis tels que dans la description et les revendications. Le composé de formule (I) peut être utilisé en tant que médicament.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211026&DB=EPODOC&CC=CA&NR=2903588C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211026&DB=EPODOC&CC=CA&NR=2903588C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SCHULZ-GASCH, TANJA</creatorcontrib><creatorcontrib>ROGERS-EVANS, MARK</creatorcontrib><creatorcontrib>ROEVER, STEPHAN</creatorcontrib><creatorcontrib>GRETHER, UWE</creatorcontrib><creatorcontrib>KIMBARA, ATSUSHI</creatorcontrib><creatorcontrib>NETTEKOVEN, MATTHIAS</creatorcontrib><creatorcontrib>BENDELS, STEFANIE</creatorcontrib><title>PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS</title><description>Abstract The invention relates to a compound of formula (I) 2 R ,R3 N N---N I R1N%---N \ A¨R4 (I) including pharmaceutically acceptable salts or esters thereof. The compound of formula (I) can be used as a medicament, for example, in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis. Date recue/Date Received 2020-08-28
L'invention concerne un composé de formule (I) où A et R1 à R4 sont définis tels que dans la description et les revendications. Le composé de formule (I) peut être utilisé en tant que médicament.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNAOCA3y9HNVcHEN8gxzDPEMcw1WcAxWcHYyUghydXYNCPEPUnB09_fzDA4J5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORpYGxqYWFs7GhFUAAORGJA4</recordid><startdate>20211026</startdate><enddate>20211026</enddate><creator>SCHULZ-GASCH, TANJA</creator><creator>ROGERS-EVANS, MARK</creator><creator>ROEVER, STEPHAN</creator><creator>GRETHER, UWE</creator><creator>KIMBARA, ATSUSHI</creator><creator>NETTEKOVEN, MATTHIAS</creator><creator>BENDELS, STEFANIE</creator><scope>EVB</scope></search><sort><creationdate>20211026</creationdate><title>PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS</title><author>SCHULZ-GASCH, TANJA ; ROGERS-EVANS, MARK ; ROEVER, STEPHAN ; GRETHER, UWE ; KIMBARA, ATSUSHI ; NETTEKOVEN, MATTHIAS ; BENDELS, STEFANIE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2903588C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SCHULZ-GASCH, TANJA</creatorcontrib><creatorcontrib>ROGERS-EVANS, MARK</creatorcontrib><creatorcontrib>ROEVER, STEPHAN</creatorcontrib><creatorcontrib>GRETHER, UWE</creatorcontrib><creatorcontrib>KIMBARA, ATSUSHI</creatorcontrib><creatorcontrib>NETTEKOVEN, MATTHIAS</creatorcontrib><creatorcontrib>BENDELS, STEFANIE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SCHULZ-GASCH, TANJA</au><au>ROGERS-EVANS, MARK</au><au>ROEVER, STEPHAN</au><au>GRETHER, UWE</au><au>KIMBARA, ATSUSHI</au><au>NETTEKOVEN, MATTHIAS</au><au>BENDELS, STEFANIE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS</title><date>2021-10-26</date><risdate>2021</risdate><abstract>Abstract The invention relates to a compound of formula (I) 2 R ,R3 N N---N I R1N%---N \ A¨R4 (I) including pharmaceutically acceptable salts or esters thereof. The compound of formula (I) can be used as a medicament, for example, in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis. Date recue/Date Received 2020-08-28
L'invention concerne un composé de formule (I) où A et R1 à R4 sont définis tels que dans la description et les revendications. Le composé de formule (I) peut être utilisé en tant que médicament.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2903588C |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T18%3A50%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SCHULZ-GASCH,%20TANJA&rft.date=2021-10-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2903588C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |